Slide 1Approach to Acid-Base Disorders Antonio Renato B. Herradura, M.D. F.P.C.P, F.P.C.C.P UERMMMC Slide 2 Importance of Acid-Base Disorders Among the most common clinical…

Slide 1RACE II RAte Control Efficacy in Permanent Atrial Fibrillation A Randomized Comparison of Lenient Rate Control versus Strict Rate Control Concerning Morbidity and…

Slide 1Regulatory Perspectives on the Thorough QT/QTc Study 2005 FDA/Industry Workshop Washington DC September 16, 2005 Juan (Joanne) Zhang, Ph.D. CDER/FDA *Acknowledgement:…

Slide 11 Supersensitive magnetocardiographic system for early recognition, precise diagnostics and monitoring of heart diseases 12.10.2006 Kiev Dr.Volodymyr Sosnytskyy +38(044)5013072…

Slide 1Pharmacology of Antiarrhytmic Drug M. Saifur Rohman, dr. SpJP. PhD. FICA Department of Cardiology and Vascular Medicine Faculty of Medicine, Brawijaya University Slide…

Slide 1Anne-Marie Anagnostopoulos, MD Non-Invasive Conference December 9, 2009 Slide 2 Outline  History and Epidemiology  Anatomy and Embryology  Spectrum of TOF…

1.Sudden Cardiac Death Rosco Gore2. Definition The natural death from cardiac causes, heralded by abrupt loss of consciousness within 1 hour of the onset of an acute change…

1.Vimala Colaco2. Atropine• Treatment of sinus pulseless electrical activity,bradycardia, or asystole.. Neonates and children: 0.02mg/kg intratracheal (max: 0.5mg); may…

1.Vimala Colaco2. Atropine• Treatment of sinus pulseless electrical activity,bradycardia, or asystole.. Neonates and children: 0.02mg/kg intratracheal (max: 0.5mg); may…

1. ARTERIOSCLEROSIS–ATHEROSCLEROSIS–A general hardening of the arteries A a specific type of arteriosclerosis, refers to the accumulation of lipid in the walls of the…